News – Page 498 – Endpoints News

After architecting Agios’ oncology exit and R&D pivot, Jackie Fouse hands keys to former Alexion exec

3 years ago

How interest in a single cancer drug led to Ipsen's takeover of Epizyme

3 years ago

UCB adds real patient voices from across arthritis conditions in ‘Advantage Hers’ campaign

3 years ago

#DIA22: Revamping the FDA's prized accelerated approvals

3 years ago

#DIA22: Fireside chat with Zachary Brennan and Aaron Kesselheim

3 years ago

Following in FDA's footsteps, EMA plots transition to reviewing raw clinical data

3 years ago

Jubilant HollisterStier pumps $77M into Montreal facility to double its capacity

3 years ago

Horizon Therapeutics scores 'Mama Durant' in campaign to raise awareness for rare eye disease

3 years ago

California to manufacture and produce its own insulin as Congress debates $35 monthly cap

3 years ago

MarketingRx roundup: Pfizer bows high-risk Covid treatment ads; Lilly drops first social ads after alopecia approval

3 years ago

Rx-to-OTC switches: What FDA's new proposed rule means for pharma companies

3 years ago

More than Covid: Moderna updates its look, preps corporate campaign as it builds broader mRNA technology brand

3 years ago

Surge of BA.5: Biden officials to stay the course with Covid strategy, prep for bivalent boosters in October

3 years ago

Connect shrinks timeline for atopic dermatitis data; Bicycle's wheels keep turning with Genentech

3 years ago

Quiet neurodegenerative disease startup secures $100M from unnamed investors

3 years ago

FDA lifts hold on Greenwich LifeSciences as biotech will forge ahead with immunotherapy drug candidate

3 years ago

Despite trial discontinuations, Rhythm’s genetic obesity drug effective in another rare indication

3 years ago

'Approvability has been put to bed': Aldeyra says eye drop clears three dry eye signals en route to FDA

3 years ago

Flagship unwraps new AI biotech that looks to predict variants before they’re here

3 years ago

Gene editing for heart disease: Verve kicks off landmark base editing trial

3 years ago

No surrender: A group of marquee biotech players bets on the $350M PhIII resurrection story of a heavyweight ...

3 years ago

Big Pharma vet teams with former Doudna pupil to launch new epigenome startup

3 years ago

Can positive but exploratory data entice investors to $150M raise in a bear market? Pliant will find out

3 years ago

Access to methotrexate in limbo post-Roe — report

3 years ago

First page Previous page 495 496 497498499 500 501 Next page Last page